Cargando…

Critical Illness Secondary to Synthetic Cannabinoid Ingestion

IMPORTANCE: Synthetic cannabinoids (SCs), commonly known as K2, spice, or fake weed, are cheap, artificially manufactured recreational drugs that have emerged as a major public health threat in various regions of the US. OBJECTIVE: To describe the clinical manifestations of SC intoxication. DESIGN,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kourouni, Ismini, Mourad, Bashar, Khouli, Hassan, Shapiro, Janet M., Mathew, Joseph P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372325/
https://www.ncbi.nlm.nih.gov/pubmed/32687586
http://dx.doi.org/10.1001/jamanetworkopen.2020.8516
_version_ 1783561290349805568
author Kourouni, Ismini
Mourad, Bashar
Khouli, Hassan
Shapiro, Janet M.
Mathew, Joseph P.
author_facet Kourouni, Ismini
Mourad, Bashar
Khouli, Hassan
Shapiro, Janet M.
Mathew, Joseph P.
author_sort Kourouni, Ismini
collection PubMed
description IMPORTANCE: Synthetic cannabinoids (SCs), commonly known as K2, spice, or fake weed, are cheap, artificially manufactured recreational drugs that have emerged as a major public health threat in various regions of the US. OBJECTIVE: To describe the clinical manifestations of SC intoxication. DESIGN, SETTING, AND PARTICIPANTS: This case series assessed adults admitted to the intensive care unit from 2014 to 2016 with acute life-threatening complications of SC use. Data analysis was completed in October 2016. EXPOSURES: Use of SCs such as K2, spice, or other synthetic versions of cannabinoids. MAIN OUTCOMES AND MEASURES: Data collected included patient demographic data, medical history, presenting symptoms, physical findings, laboratory and imaging data, and intensive care unit and hospital course. RESULTS: Thirty patients (mean age, 41 years [range, 21-59 years]; 24 men [80%]) with SC ingestion were admitted to the intensive care unit over a 2-year period. Thirteen patients were undomiciled. The majority had a history of polysubstance abuse, psychiatric illness, or personality disorder. The admission diagnoses were coma (10 patients [33%]), agitation (10 patients [33%]), and seizure (6 patients [20%]). Eighteen patients (60%) had acute respiratory failure, and tracheal intubation was required in 21 patients (70%) for either airway protection or acute respiratory failure. Rhabdomyolysis was noted in 8 patients (26%). A man developed transient cerebral edema with loss of gray-white differentiation but had complete recovery. A woman with history of asthma died of acute respiratory distress syndrome. All patients underwent routine toxicology testing, which was unrevealing in 16 cases and revealed coingestion in the remainder. Sixteen patients (53%) left the hospital against medical advice. CONCLUSIONS AND RELEVANCE: Ingestion of SCs can lead to life-threatening complications, including severe toxic encephalopathy, acute respiratory failure, and death. Synthetic cannabinoids are undetectable in routine serum and urine toxicology testing but can be suspected on the basis of history and clinical presentation, which may include extreme agitation or coma. Frontline clinicians must be aware of the presentation and be vigilant in suspecting SC intoxication.
format Online
Article
Text
id pubmed-7372325
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-73723252020-07-22 Critical Illness Secondary to Synthetic Cannabinoid Ingestion Kourouni, Ismini Mourad, Bashar Khouli, Hassan Shapiro, Janet M. Mathew, Joseph P. JAMA Netw Open Original Investigation IMPORTANCE: Synthetic cannabinoids (SCs), commonly known as K2, spice, or fake weed, are cheap, artificially manufactured recreational drugs that have emerged as a major public health threat in various regions of the US. OBJECTIVE: To describe the clinical manifestations of SC intoxication. DESIGN, SETTING, AND PARTICIPANTS: This case series assessed adults admitted to the intensive care unit from 2014 to 2016 with acute life-threatening complications of SC use. Data analysis was completed in October 2016. EXPOSURES: Use of SCs such as K2, spice, or other synthetic versions of cannabinoids. MAIN OUTCOMES AND MEASURES: Data collected included patient demographic data, medical history, presenting symptoms, physical findings, laboratory and imaging data, and intensive care unit and hospital course. RESULTS: Thirty patients (mean age, 41 years [range, 21-59 years]; 24 men [80%]) with SC ingestion were admitted to the intensive care unit over a 2-year period. Thirteen patients were undomiciled. The majority had a history of polysubstance abuse, psychiatric illness, or personality disorder. The admission diagnoses were coma (10 patients [33%]), agitation (10 patients [33%]), and seizure (6 patients [20%]). Eighteen patients (60%) had acute respiratory failure, and tracheal intubation was required in 21 patients (70%) for either airway protection or acute respiratory failure. Rhabdomyolysis was noted in 8 patients (26%). A man developed transient cerebral edema with loss of gray-white differentiation but had complete recovery. A woman with history of asthma died of acute respiratory distress syndrome. All patients underwent routine toxicology testing, which was unrevealing in 16 cases and revealed coingestion in the remainder. Sixteen patients (53%) left the hospital against medical advice. CONCLUSIONS AND RELEVANCE: Ingestion of SCs can lead to life-threatening complications, including severe toxic encephalopathy, acute respiratory failure, and death. Synthetic cannabinoids are undetectable in routine serum and urine toxicology testing but can be suspected on the basis of history and clinical presentation, which may include extreme agitation or coma. Frontline clinicians must be aware of the presentation and be vigilant in suspecting SC intoxication. American Medical Association 2020-07-20 /pmc/articles/PMC7372325/ /pubmed/32687586 http://dx.doi.org/10.1001/jamanetworkopen.2020.8516 Text en Copyright 2020 Kourouni I et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Kourouni, Ismini
Mourad, Bashar
Khouli, Hassan
Shapiro, Janet M.
Mathew, Joseph P.
Critical Illness Secondary to Synthetic Cannabinoid Ingestion
title Critical Illness Secondary to Synthetic Cannabinoid Ingestion
title_full Critical Illness Secondary to Synthetic Cannabinoid Ingestion
title_fullStr Critical Illness Secondary to Synthetic Cannabinoid Ingestion
title_full_unstemmed Critical Illness Secondary to Synthetic Cannabinoid Ingestion
title_short Critical Illness Secondary to Synthetic Cannabinoid Ingestion
title_sort critical illness secondary to synthetic cannabinoid ingestion
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372325/
https://www.ncbi.nlm.nih.gov/pubmed/32687586
http://dx.doi.org/10.1001/jamanetworkopen.2020.8516
work_keys_str_mv AT kourouniismini criticalillnesssecondarytosyntheticcannabinoidingestion
AT mouradbashar criticalillnesssecondarytosyntheticcannabinoidingestion
AT khoulihassan criticalillnesssecondarytosyntheticcannabinoidingestion
AT shapirojanetm criticalillnesssecondarytosyntheticcannabinoidingestion
AT mathewjosephp criticalillnesssecondarytosyntheticcannabinoidingestion